Inhibition of complement C1s by sutimlimab (SUT) in patients with cold agglutinin disease (CAD): results on efficacy and safety from the randomized, placebo-controlled phase 3 CADENZA study (NCT03347422)

被引：0
|
作者：
Roeth, A. [1 ]
Berentsen, S. [2 ]
Barcellini, W. [3 ]
D'Sa, S. [4 ]
Jilma, B. [5 ]
Michel, M. [6 ]
Weitz, I. C. [7 ]
Yamaguchi, M. [8 ]
Nishimura, J. -i [9 ]
Vos, J. M. [10 ,11 ]
Storek, M. [12 ]
Wong, N. W. [12 ]
Patel, P. [12 ]
Jiang, X. [12 ]
Vagge, D. [13 ]
Wardecki, M. [14 ]
Shafer, F. [12 ]
Lee, M. [12 ]
Broome, C. M. [15 ]
机构：
[1] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany
[2] Haugesund Hosp, Dept Res & Innovat, Haugesund, Norway
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[4] Univ Coll London Hosp NHS Fdn Trust, UCLH Ctr Waldenstroms Macroglobulinemia & Related, London, England
[5] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[6] UPEC, Henri Mondor Univ Hosp, Assistance Publ Hop Paris, Creteil, France
[7] USC, Keck Sch Med, Jane Anne Nohl Div Hematol, Dept Med, Los Angeles, CA USA
[8] Ishikawa Prefectural Cent Hosp, Dept Hematol, Kanazawa, Japan
[9] Osaka Univ, Osaka, Japan
[10] Amsterdam UMC, Amsterdam, Netherlands
[11] Sanquin, Dept Hematol, Amsterdam, Netherlands
[12] Sanofi, Cambridge, England
[13] IQVIA, Bangalore, Karnataka, India
[14] Sanofi, Warsaw, Poland
[15] MedStar Georgetown Univ Hosp, Div Hematol, Washington, DC USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V575
引用
收藏
页码：172 / 173
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn's Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study
    Vermeire, Severine
    Rubin, David T.
    Watanabe, Mamoru
    Schreiber, Stefan
    Mehta, Rajiv
    Roblin, Xavier
    Genovese, Mark C.
    Masior, Tomasz
    Barron, Rahul
    Le Brun, Franck-Olivier
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S673 - S675
  • [32] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
    Takeshima, Takao
    Sakai, Fumihiko
    Hirata, Koichi
    Imai, Noboru
    Matsumori, Yasuhiko
    Yoshida, Ryuji
    Peng, Cheng
    Cheng, Sunfa
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (06): : 927 - 935
  • [33] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study
    Zhang, Jianzhong
    Gu, Jun
    Zheng, Jie
    Zheng, Min
    Wang, Gang
    Gu, Yihua
    Okun, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232
  • [34] Efficacy and Safety of RBX2660 in Patients After First Recurrence of Clostridioides difficile Infection - Results From a Phase 3, Randomized, Placebo-Controlled Study
    Khanna, Sahil
    Tillotson, Glenn
    Ando, Masakazu
    Bancke, Lindy
    Harvey, Adam
    Garey, Kevin W.
    LaPlante, Kerry
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S138 - S138
  • [35] EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: AN ANALYSIS OF THE ITALIAN PATIENTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    Andreone, P.
    Mazzella, G.
    Invernizzi, P.
    Floreani, A.
    Picaro, L. A.
    Adorini, L.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E81 - E81
  • [36] Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3, randomized, placebo-controlled trial
    Jemec, Gregor
    Gottlieb, Alice
    Forman, Seth
    Giamarellos-Bourboulis, Evangelos
    Reguiai, Ziad
    Gu, Yihua
    Okun, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB45 - AB45
  • [37] EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: AN ANALYSIS OF THE ITALIAN PATIENTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    Floreani, A.
    Andreone, P.
    Invernizzi, P.
    Mazzella, G.
    Owens-Grillo, J.
    Malecha, E. Smoot
    Macconell, L.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E74 - E74
  • [38] Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial
    McDonald, C.
    Wu, S.
    Gulati, S.
    Komaki, H.
    Ruiz-Garcia, M.
    Kostera-Pruszczyk, A.
    Vlodavets, D.
    Chae, J.
    Jong, Y.
    Karachunski, P.
    Statland, J.
    Lorentzos, M.
    Penematsa, V
    Chou, C.
    Lin, M.
    Werner, C.
    Trifillis, P.
    Gordon, G.
    Klein, M.
    NEUROMUSCULAR DISORDERS, 2022, 32
  • [39] Efficacy and safety of rasagiline monotherapy in Japanese patients with early Parkinson's disease: A phase 3, randomized, double-blind, placebo-controlled, multicenter study
    Hattori, N.
    Takeda, A.
    Takeda, S.
    Nishimura, A.
    Kitagawa, T.
    Mochizuki, H.
    Nagai, M.
    Takahashi, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 231 - 232
  • [40] Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    McDonald, Craig M.
    Wu, Shiwen
    Gulati, Sheffali
    Komaki, Hirofumi
    Escobar, Rosa E.
    Kostera-Pruszczyk, Anna
    Vlodavets, Dmitry
    Chae, Jong-Hee
    Jong, Yuh-Jyh
    Karachunski, Peter
    Statland, Jeffrey
    Lorentzos, Michelle
    Penematsa, Vinay
    Chou, Connie
    Lin, Min
    Werner, Christian
    Trifillis, Panayiota
    Gordon, Gregory
    Koladicz, Karyn
    Mastrandrea, Nicholas
    Klein, Matthew
    NEUROLOGY, 2023, 100 (17)
12345